Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Drops By 19.0%

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,790,000 shares, a drop of 19.0% from the October 15th total of 2,210,000 shares. Based on an average daily trading volume, of 458,300 shares, the days-to-cover ratio is presently 3.9 days. Approximately 2.1% of the company’s shares are short sold.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bleakley Financial Group LLC acquired a new position in shares of Compass Therapeutics in the 1st quarter valued at approximately $80,000. Renaissance Technologies LLC grew its holdings in shares of Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after purchasing an additional 12,315 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Compass Therapeutics by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after purchasing an additional 71,008 shares during the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in shares of Compass Therapeutics during the 2nd quarter valued at approximately $68,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Trading Down 13.2 %

CMPX stock traded down $0.21 during trading hours on Friday, hitting $1.38. 1,348,934 shares of the stock were exchanged, compared to its average volume of 455,768. The firm has a market capitalization of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92. The company has a 50-day simple moving average of $1.75 and a two-hundred day simple moving average of $1.42. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. On average, equities research analysts predict that Compass Therapeutics will post -0.37 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, November 11th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research report on Monday, September 16th. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday. Finally, Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $5.00 to $4.00 in a report on Friday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.75.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.